Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
Looking for a particular Vaxxas employee's phone or email?
The Vaxxas annual revenue was $7 million in 2026.
David Peacock is the CEO of Vaxxas.
94 people are employed at Vaxxas.
Vaxxas is based in Brisbane, Queensland.
The NAICS codes for Vaxxas are [32541, 3254, 325414, 32, 325].
The SIC codes for Vaxxas are [283, 28].